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Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterized by over-
activation and dysregulation of the alternative complement pathway. Its estimated preva-
lence is 1–2 per million.The disease is characterized by thrombotic microangiopathy, which
causes anemia, thrombocytopenia, and acute renal failure. aHUS has more severe course
compared to typical (infection-induced) HUS and is frequently characterized by relapses that
leads to end stage renal disease. For a long time, kidney transplantation for these patients
was contraindicated because of high rate of recurrence and subsequent renal graft loss.
The post-kidney transplantation recurrence rate largely depends on the pathogenetic mech-
anisms involved. However, over the past several years, advancements in the understanding
and therapeutics of aHUS have allowed successful kidney transplantation in these patients.
Eculizumab, which is a complement C5 antibody that inhibits complement factor 5a and
subsequent formation of the membrane-attack complex, has been used in prevention and
treatment of post-transplant aHUS recurrence. In this paper, we present two new cases
of aHUS patients who underwent successful kidney transplantation in our center with the
use of prophylactic and maintenance eculizumab therapy that have not been published
before.The purpose of reporting these two cases is to emphasize the importance of using
eculizumab as a prophylactic therapy to prevent aHUS recurrence post-transplant in high-
risk patients. We will also review the current understanding of the genetics of aHUS, the
pathogenesis of its recurrence after kidney transplantation, and strategies for prevention
and treatment of post-transplant aHUS recurrence.
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INTRODUCTION
Atypical hemolytic uremic syndrome (aHUS) is a rare disorder
characterized by over-activation and dysregulation of the alter-
native complement pathway. Its estimated prevalence is 1–2 per
million (1). The disease is characterized by thrombotic microan-
giopathy (TMA), which causes anemia, thrombocytopenia, and
acute renal failure. aHUS has more severe course compared to
typical (infection-induced) HUS and is frequently characterized
by relapses that leads to end stage renal disease (ESRD). For a long
time,kidney transplantation for these patients was contraindicated
because of high rate of recurrence and subsequent renal graft loss.
The post-kidney transplantation recurrence rate largely depends
on the pathogenetic mechanisms involved. However, over the past
several years, advancements in the understanding and therapeutics
of aHUS have allowed successful kidney transplantation in these
patients. Eculizumab, which is a complement C5 antibody that
inhibits complement factor 5a (C5a) and subsequent formation
of the membrane-attack complex (MAC), has been used in pre-
vention and treatment of post-transplant aHUS recurrence. In this
paper, we present two new cases of aHUS patients who underwent
successful kidney transplantation in our center with the use of pro-
phylactic and maintenance eculizumab therapy that have not been
published before. The purpose of reporting these two cases is to
emphasize the importance of using eculizumab as a prophylactic
therapy to prevent aHUS recurrence post-transplant in high-risk
patients. We will also review the current understanding of the
genetics of aHUS, the pathogenesis of its recurrence after kidney




In 2011, a 25-year-old Caucasian female developed ESRD due
to aHUS. Her initial symptom was shortness of breath and
she was found to have severe hypertension, acute kidney injury
with serum creatinine of 11.4 mg/dl, anemia with hemoglobin of
5 g/dl, elevated LDH, and thrombocytopenia with platelet count of
20,000/dl. Additional work-up revealed schistocytosis on periph-
eral smear. She underwent kidney biopsy that revealed TMA
involving glomeruli and small vessels. A diagnosis of thrombotic
thrombocytopenic purpura (TTP)/HUS was initially made. She
received high-dose pulse steroids and four sessions of plasma-
pheresis. Despite therapy, the disease continued to progress and
the patient became hemodialysis dependent. One year later, she
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was evaluated in our institution for kidney transplantation. Our
work-up included ADAMTS13 level, which came back normal and
genetic analysis, which confirmed a mutation (c.1933dup A) of
complement factor-H (CFH), a variant in exon 13 (SCR11) of
the gene CFH. This variant has been identified before and most
likely associated with aHUS (personal communication with the
Molecular research renal laboratory at the University of Iowa).
In mid-2014, she underwent living unrelated kidney transplant.
Twenty-four hours prior to transplantation, she received a dose
of eculizumab 1200 mg intravenously (IV). Immunosuppression
consisted of induction therapy with four doses of intravenous
thymoglobulin and 4-day methylprednisolone taper, and main-
tenance therapy with tacrolimus, mycophenolate mofetil, and
prednisone. She had immediate graft function and her serum crea-
tinine was 1.0 mg/dl at the time of discharge. After transplantation,
she received weekly eculizumab 900 mg IV for 4 weeks started on
day 1 post-transplant, and then 1200 mg IV biweekly starting at
week 5 post-transplant; we have utilized the eculizumab protocol
recommended by the manufacturing company. Serum comple-
ment 3 (C3) level was 37 mg/dl (normal 79–152 mg/dl) at the time
of the transplantation and increased to 58 mg/dl 3 months post-
transplant. Haptoglobin and LDH levels were normal at the time
of transplantation and remained normal afterwards. Hemoglo-
bin was 9.5 g/dl at the time of transplantation and increased to
12.5 g/dl few weeks after. Renal allograft function has remained
stable with most recent serum creatinine of 1.1 mg/dl.
CASE 2
In 2002, a 23-year-old Caucasian female developed ESRD due to
TMA disorder. Her initial presentation included nausea, vomiting,
and jaundice. She was found to have evidence of hemolytic ane-
mia with schistocytosis, thrombocytopenia,and acute renal failure.
The initial diagnosis was thought to be TTP. She did not undergo
a kidney biopsy. She was started on plasmapheresis but her disease
did not respond to the treatment. She also received chemotherapy
with vincristine with no response. Her hematologic parameters
continued to worsen and eventually splenectomy was required. At
the time of diagnosis, she was started on dialysis and remained
dialysis depended thereafter. In 2003, she received living unrelated
donor kidney transplantation. Her maintenance immunosuppres-
sions were prednisone, mycophenolate mofetil, and sirolimus. In
2005, she developed a diarrheal illness, and her laboratory evalua-
tion showed recurrence of thrombotic microangiopathy including
hemolytic anemia, thrombocytopenia, and renal failure. At that
time, she was initiated on plasmapheresis; however, her allograft
function did not respond to the therapy and she was started
again on dialysis. With the recurrence of TMA post-transplant,
additional laboratory work-up revealed normal ADAMTS13 level
and low C3 level. In 2012, she was evaluated for second kidney
transplantation in our institution. Genetic testing was performed
and revealed that the patient is heterozygous for two mutations
in complement factor related proteins (CFHRs) that may cause
aHUS. In fact, these two mutations were not identified previously
in aHUS database. The mutations were deletion (CFH int20br-
CFHR3) on allele 1 and duplication in (CFHR1 int4–CFHR4 block
7/2 prime) on allele 2. In early 2014, the patient received a suc-
cessful six-antigen match deceased donor kidney transplant. A
dose of eculizumab 1200 mg was administered approximately 24 h
prior to transplantation. After transplantation, she received weekly
eculizumab 900 mg IV for 4 weeks started on day 1 post-transplant,
and then 1200 mg IV biweekly started on week 5 post-transplant.
At the time of transplantation, her hemoglobin was 11.2 g/dl
and haptoglobin level, LDH level, platelet count, and C3 level
were all normal. Six months after transplantation, her hemoglo-
bin increased to 13.5 g/dl. Haptoglobin level, C3 level, LDH, and
platelets count remained within normal limits. Allograft function
has been excellent so far with most recent serum Creatinine of
0.5 mg/dl.
ETIOLOGY
Atypical HUS can be genetic, acquired, or idiopathic, whereas
typical HUS (or diarrhea-associated HUS) is usually triggered by
infection with certain strains of Escherichia coli that produce pow-
erful Shiga-like exotoxins. There are also other forms of HUS that
are secondary to other infections such as Streptococcus pneumo-
niae and HIV or secondary to malignancies, drugs, pregnancy,
systemic lupus erythematous (SLE), and anti-phospholipid anti-
body syndrome (2, 3). More recently, HUS has been described
in coagulation dysregulation disorders associated with mutations
in certain genes; such as the gene encoding diacylglycerol kinase
(DGKE) (4).
Atypical HUS is less common than other types of HUS and
is characterized by a worse outcome (1, 2, 5). Overall, aHUS
accounts for 5% of all HUS cases (2). The incidence of aHUS
in the United States is approximately 1–2 per million (1). Atypical
HUS may develop in patients of any age, although the major-
ity of cases develop in childhood (1, 2). The disease may have
a familial or a sporadic pattern. Most of aHUS cases are linked
to genetic abnormalities that involve genes encoding regulatory
complement factors. The relationship between low-plasma C3
and HUS was first described by Cameron in 1973 (1, 2, 6). Sev-
eral mutations in genes encoding regulatory complement proteins
have been identified over the last decade. Atypical HUS is the
result of abnormal activation and dysregulation of the alternative
complement pathway.
COMPLEMENT SYSTEM AND ITS REGULATION
The alternative complement pathway is persistently activated in
plasma. This activation is usually minimal and leads to minor
attacks on all structures that the final complement product comes
in contact with (1, 2, 5, 7). Under normal conditions, this process
is very well regulated by regulatory complement factors. The
alternative complement pathway is activated by the spontaneous
hydrolysis of complement factor 3 (C3). C3 hydrolysis produces
the fragment C3b, which binds to complement factor B (CFB),
which in turn is cleaved by complement factor D (CFD) to C3bBb,
which is called the C3 convertase. This complex generates more
C3b through an amplification loop. As the process continues, more
C3b is produced, and eventually [(C3b)2 BbP] is formed. This
complex acts as the C5 convertase that cleaves complement factor
5 (C5). Cleavage of C5 generates fragment C5b, which activates the
terminal complement pathway by combining with complement
factors 6, 7, 8, and 9 to form C5b–9, the MAC. MAC is responsible
for endothelial cell damage and leads to micro-thrombosis.
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To make this process regulated and prevent over-activation of
the alternative complement pathway, different regulatory comple-
ment proteins are produced and activated under normal condi-
tions (1, 2). Complement receptor 1 (CR1 or CD35), CFH, and
decay-accelerating factor (DAF or CD55) compete with CFB in
binding with C3b on the cell surface and can remove Bb from
a C3bBb complex. This leads to decreased C3 convertase pro-
duction. The formation of a C3 convertase is also prevented by
complement factor-I (CFI) that cleaves C3b into its inactive form.
CFI requires a C3b binding protein co-factor such as CFH, CR1,
membrane co-factor protein (MCP or CD46), or thrombomod-
ulin (THBD). CFH related proteins (CFHR1–5) comprise a group
of five plasma proteins (CFHR1–5), and each member of this
group binds to the central complement component C3b (8). The
specific role of each CFHR protein in complement regulation
remains unclear; however, they probably play an inhibitory role
on C3 convertase and C5 convertase activity (8).
GENETIC BASIS OF aHUS
Atypical HUS is the result of abnormalities in the complement
regulatory proteins mentioned above. These abnormalities lead to
abnormal activation and dysregulation of the alternative com-
plement pathway. Over the last several years, loss-of-function
mutations have been identified in CFH, MCP, CFI, and THBD
in some patients presenting with atypical HUS (2, 9). Anti-factor-
H and I antibodies have also been recognized in other patients,
particularly in children. Gain-of-function mutations in C3 and
CFB have also been identified in small percentage of patients
with aHUS. Overall, mutations in complement regulatory fac-
tors or anti-factor-H and I antibodies have been documented
in 60–70% of patients with aHUS (2, 5, 9). The remainder of
patients with aHUS probably have genetic abnormalities that yet
to be identified. Most of the identified mutations have an incom-
plete penetrance. It is estimated that the penetrance for most of
these mutations is about 50% (1, 2, 10–15). Table 1 summarizes
the different characteristics of known mutation that have been
associated with aHUS.
Complement factor-H mutations
These mutations are loss-of-function mutations. CFH mutations
are the most frequent genetic abnormality identified in patients
with aHUS (2). Up until now, eighty seven mutations in CFH
associated with aHUS have been identified (16). They are found
in 20–30% of aHUS patients (17–19). Seventy-five percent of the
patients are heterozygous and the remainder is homozygous. In
30% of the patients, the mutations cause quantitative deficiency
in CFH leading to decrease in CFH and C3 levels. The remainder
has functional deficiency of CFH. In the latter case, CFH and C3
levels are usually in the normal range (9, 18, 19).
Anti-factor-H antibodies
Auto-antibodies to CFH cause functional deficiency of CFH. They
bind to factor-H and inhibit its binding to C3b (2, 20, 21). Anti-
factor-H antibodies are responsible for 6% of the aHUS cases.
Low-C3 levels are observed in 40–60% of patients with anti-
factor-H antibodies. The majority of these patients also have other
mutations in CFH, CFI, C3, CD46 (22), or mutations in genes
encoding CFHR proteins 1–5 such as deletions or rearrangements
(8, 22, 23).
Membrane co-factor protein mutations
These are loss-of-function mutations. The abnormal MCP binds
weakly to C3b and loses its activity as co-factor (1, 2, 9, 17, 24, 25).
Thus far, 28 mutations in MCP have been identified as a cause of
aHUS (16). MCP mutations account for 10–15% of aHUS cases.
They are more common in children than in adults. In up to 75% of
the cases, MCP mutations cause low-MCP expression on periph-
eral leukocytes, which can be used as a diagnostic tool. However,
in the remainder of cases, MCP mutations do not cause low-MCP
expression (25). Around 30% of patients with MCP mutations
have low-C3 level (2, 5, 7, 9, 17, 25).
Table 1 | Characteristics of genetic mutations associated with aHUS and risk of recurrence after kidney transplantation without prevention
or treatment.
Mutation aHUS incidence Type of deficiency C3 level Risk of recurrence
post-transplant
CFH 20–30% 70% Qualitative and 30% quantitative Low in 30% (quantitative deficiency) 70–80%
MCP 10–15% 70% Qualitative and 30% quantitative Low in 30% (quantitative deficiency) Low (unless associated with
other mutations)
CFI 5–10% 70% Qualitative and 30% quantitative Low in 30% (quantitative deficiency) 70–80%
CFB 1–4% – Always low 100% (only 4 cases reported)
THBD 3–5% – Low in 50% Unknown but probably very low
C3 2–10% Majority are quantitative Low in 80% 40%
Anti-CFH Abs 6% N/A Low in 40–60% 40–70% Depending on
associated mutations
CFHR 1–5 Unknown Usually qualitative Normal unless it is associated with
other mutations
Unknown
Combined mutations 10–12% Variable Variable Variable
aHUS, atypical hemolytic uremic syndrome; C3, complement factor 3; CFH, complement factor-H; MCP, membrane co-factor protein; CFI, complement factor-I;
CFB, complement factor B; THBD, thrombomodulin; CFHR, complement factor-H related proteins.
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Complement factor-I mutations
These are loss-of-function mutations. CFI mutations account for
5–10% of aHUS cases (21, 26–28). To date, there are 11 muta-
tions in CFI that have been associated with aHUS (16). Similar to
CFH mutations, CFI mutations may lead to either a quantitative
or functional deficiency in CFI. In 30% of the patients, the muta-
tions cause quantitative deficiency in CFI leading to decrease in
both CFI and C3 levels (2, 7, 9, 21, 26–28).
Thrombomodulin mutations
These are also loss-of-function mutations. Cells with mutant
THBD are less efficient at inactivating C3b. THBD mutations
account for 3–5% of patients with aHUS. C3 levels are low in
50% of patients THBD mutations (2, 7, 9, 12, 29).
Complement factor B mutations
Complement factor B mutations are usually gain-of-function
mutations and result in increased stability of C3 convertase and
its resistance to degradation. CFB mutations account for 1–4% of
patients with aHUS (7, 30). Patients with CFB mutations always
have low-serum C3 level (2, 7, 9, 30–32).
Complement component 3 mutations
The mutant C3 binds weakly to MCP and/or CFH, which leads to
indirect gain-of-function for C3 activity (7, 33). Therefore, bind-
ing of CFB to C3b increases and more C3 convertase is formed.
C3 mutations account for 2–10% of patients with aHUS. In 80%
of cases, serum C3 level is low (2, 7, 9, 32, 33).
Combined mutations
Up to 10–12% of patients with aHUS have two or more mutations
in different complement factors (32). This suggests that aHUS may
result from the additive effects of several genetic factors (2).
Complement factor-H related proteins genetic polymorphism
Genetic polymorphisms in CFH related proteins may create a
slight increase in predisposition to aHUS and could influence the
severity of disease (7, 8, 26, 34–36). The area of abnormalities in
genes encoding CFHR proteins still needs further investigation.
Mutations, genetic deletions, duplications, or rearrangements in
the individual CFHR genes are associated with a number of dis-
eases including aHUS, C3 glomerulopathy, IgA nephropathy, age
related macular degeneration (AMD), and SLE (36). Rearrange-
ment that leads to the formation of hybrid CFH/CFHR1 gene has
been associated with aHUS (7, 37). A hybrid factor-H/CFHR3 gene
generated by a microhomology-mediated deletion was reported
in a familial aHUS case (38). Deletion of CFHR1/CFHR3 is
also strongly associated with the development of factor-H auto-
antibodies (36, 39–41). CFHR1 deficiency alone could modulate
the severity of aHUS associated with another mutation (26).
Genetic variants of CFHR5 were also reported in aHUS patients
(33, 42).
RISK OF RECURRENCE
Atypical HUS, unlike infection-induced HUS is associated with
very high risk of recurrence after kidney transplantation (5, 43).
Concern over the recurrence of HUS after kidney transplantation
has been recognized for a long time (44, 45). In 2003, Loirat and
Niaudet (43) studied the risk of recurrence of HUS after kidney
transplantation in children and found that the risk in patients
whose original HUS was not associated with diarrhea is higher
compared to the infection-induced HUS. Sixty-three children,
who had the non-diarrheal HUS, received 77 kidney transplants.
Thirteen patients (21%) had recurrence of HUS after one or
more grafts, and there were a total of 18 recurrences in 77 grafts
(23%). In later observational studies, the recurrence rate of HUS
in adult patients who received kidney transplantation was as high
as 50–60% (7, 43, 46–48).
Over the past few years, several studies have assessed the risk of
post-transplant aHUS recurrence and prognosis associated with
specific genetic abnormalities (7, 17, 24, 49, 50). The recurrence
rate after transplantation in aHUS patients essentially depends
on whether the mutant complement factor is membrane-bound
or circulating. Membrane-bound factors expression in the renal
allograft is determined by the donor genome. Thus, patients with
mutations in genes encoding one of these factors are not expected
to develop post-transplant aHUS recurrence. On the other hand,
the risk of post-transplant aHUS recurrence in patients with muta-
tions encoding circulating factors is expected to be high (5, 7, 24,
49, 51).
In two French case series (24, 51), the rate of post-transplant
aHUS recurrence in patients with CFH mutations was around
75–80% in 5 children and 16 adults who received 6 and 17 renal
transplants, respectively. Around the same recurrence rate was
noted in a 2006 meta-analysis of 36 renal transplantations in 27
patients with aHUS associated with CFH mutations (49). Recur-
rence of aHUS with this type of mutation was associated with poor
prognosis, leading to graft loss in 93% of patients (49).
In patients with anti-CFH antibodies, the risk of post-
transplant aHUS recurrence is not well known. Studies so far only
described a total of 12 kidney transplantations in eight patients
(1, 7, 22, 35, 52–54). The assessment of the risk is further com-
plicated by the finding that as many as 40% of patients with
anti-CFH antibodies also carried a mutation in genes encoding
complement regulatory factors, including CFH,CFI,MCP, and C3
(22). Initially, it was thought that reduction in levels of anti-CFH
antibodies with plasmapheresis and rituximab permitted success-
ful kidney transplantation in these patients, suggesting that high
anti-CFH antibody levels positively correlate with risk of post-
transplant aHUS recurrence (52, 53). However, later publications
have reported that recurrence-free transplantation is achievable
in patients with anti-CFH antibodies despite the absence of any
specific treatment (22, 53, 54).
In aHUS patients with CFI mutations, the post-transplant
recurrence rate is high and associated with poor prognosis (1, 7,
18, 20, 21, 24, 55–58). Available publications reported 10 patients,
who received 15 kidney transplants. 12 of 15 (80%) transplants
consecutively failed because of aHUS recurrence. In a paper from
2009 (26), it was found that more than half of the CFI -mutation
patients had an additional genetic susceptibility for aHUS and that
those with an isolatedCFI mutation had improved kidney survival
over those with additional mutations. Thus, the post-transplant
risk of aHUS recurrence for patients with a CFI mutation should
be reassessed in the light of this finding.
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Atypical HUS patients with MCP mutations are expected to
have a low risk of post-transplant aHUS recurrence because MCP
is a membrane-bound protein (7, 59). Therefore, the progno-
sis of patients with MCP mutations after kidney transplantation
is much better than that of patients with mutations in CFH
and CFI (7, 18, 24, 25, 59, 60). However, a recent large study
of aHUS patients revealed the unexpected recurrence of disease
after transplantation in some carriers of MCP mutations. This
is probably explained by the fact that a significant proportion
(22.6%) of patients with mutations in MCP also carried mutations
in genes encoding circulating complement factors (61). Notably,
post-transplant recurrence occurred in 7.6 and 30% of MCP
single-mutated and MCP-combined mutated patients, respectively
(61). In our previously published series (62), the only patient who
had MCP mutation did not develop disease recurrence after kidney
transplantation.
There is very limited data on the post-transplant recurrence
of aHUS in patients with THBD mutations. THBD exists both in
membrane bound and soluble forms, hence, it is not possible to
reliably predict the risk of post-transplant recurrence in carriers
of these mutations. In the available study (12) that describes seven
patients with THBD mutations, one individual experienced post-
transplant recurrence of aHUS. In another case report (29), a 19-
year-old man with aHUS secondary to a THBD mutation relapsed
twice after two kidney transplantations performed 12 years apart,
which suggests that THBD mutations may favor-relapse of aHUS
after kidney transplantation. In our previously published series
(62), there was one patient with THBD mutation who developed
early recurrence after kidney transplantation.
Atypical HUS patients with C3 mutations have reduced risk
of recurrence after transplantation although it remains high after
all (7). In a study that reported 12 kidney transplant recipients
with C3 mutations, 5 of them (42%) developed recurrence (1,
11). Most circulating C3 is synthesized by hepatocytes; however,
smaller though significant amounts are produced in other tis-
sues including the kidney. Therefore, it is possible that production
of non-mutant C3 by the graft might account for the reduced
recurrence rate (63, 64).
In aHUS patients with CFB mutations, there are four cases
reported and in all four transplants failed because of recurrence
(7, 10, 65).
POST-TRANSPLANT aHUS RECURRENCE TRIGGERS
The natural history of aHUS in kidney transplant patients varies
from that of non-kidney transplant patients (1, 5, 7). The recur-
rence of aHUS in transplants patients usually occurs within the
first year after transplantation (5, 49, 51). This is different from
non-transplant patients in whom the onset of aHUS is frequently
delayed, with up to 50% of cases presenting in adulthood (5,
66). This difference is probably driven by the environment that
kidney transplantation creates, in which multiple potential trig-
gers for aHUS recurrence exist. A meta-analysis in 1998 (67)
attempted to identify clinical risk factors associated with high risk
of aHUS recurrence in post-transplant patients. The study con-
cluded that old age at presentation, short duration between onset
of disease and ESRD or transplantation, use of living donors,
and use of calcineurin inhibitor (CNI) are all associated with
high risk of recurrence. It has been suggested that recurrence
after transplantation may be less common among patients who
have undergone a nephrectomy prior to transplantation. How-
ever, there is only once study that reported this observation. In this
study, pooled data from several series was analyzed, and recurrence
was reported among 5 of 14 patients who had undergone nephrec-
tomy compared with 27 of 35 patients who had not undergone
nephrectomy (47).
There are different mechanisms in the kidney transplantation
process that may trigger recurrence of aHUS including brain-death
related injury, ischemia–reperfusion injury, infections, the use of
immunosuppressive drugs, and rejection (5).
There is growing evidence about the role of complement acti-
vation in brain-death-induced organ injuries (5, 68, 69), which
could be a trigger for aHUS recurrence. In brain death, there is
an increased circulating C5a level that induces a release of pro-
inflammatory cytokines by the kidney and eventually leads to
increased formation of C5b–9 complex.
Ischemia-reperfusion leads to endothelial damage in kidney
allograft. Studies proposed that this damage causes reduced CFH
ability to bind to the endothelium (70), ongoing alternative path-
way activation, and increased formation of C5b–9 (5). Given
this possible role of complement activation in the pathology of
delayed graft function, there are several clinical trials that are
underway to assess the efficacy of eculizumab in prevention of
delayed graft function in deceased donor kidney transplantation
(www.Clinicaltrials.gov NCT01919346).
Many infections have been involved in triggering post-
transplant aHUS recurrence (5). These include CMV (71),
influenza virus (72–74), parvovirus B19 (75), BK virus (76), upper
respiratory tract infection (19, 77), and infectious gastroenteritis
(19, 78).
Also, immunosuppressive drugs could trigger post-transplant
aHUS recurrence (2, 5, 7). Both calcineurin- and mTOR inhibitors
have been associated with endothelial toxicity (79, 80) and post-
transplant TMA. Prolonged CNI-related ischemia is believed to
induce endothelial damage and initiate the pathogenic processes
involved in the development of TMA (7, 81). Despite the general
idea that CNI play a prominent role in stimulating post-transplant
aHUS, the only available study that assessed the risk of aHUS
recurrence with different drugs showed that mTOR inhibitor-
based regimens only were found to be an independent risk factor
for post-transplant aHUS recurrence (51). In contrast, this study
failed to identify CNI-based regimens as risk factors for post-
transplant aHUS recurrence. In addition, other studies found that
mutations in CFH and CFI genes were identified in 30% of trans-
plant recipients with CNI-induced de novo post-transplant aHUS
(5, 7, 82). This suggests that factors, resulting in complement over-
activation may be required for CNI-induced endothelial toxicity to
clinically manifest. Interestingly, in the context of post-transplant
CNI toxicity, systemic aHUS, unlike localized renal TMA, usu-
ally fails to respond to reduction or temporary discontinuation
of CNI therapy (83) and respond dramatically to complement
blockade (84). In an attempt to reduce the burden of insults to the
graft endothelium, the CTLA-4-Ig fusion protein belatacept, which
does not cause any endothelial toxicity, might be a promising
alternative to calcineurin and mTOR inhibitors for maintenance
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immunosuppressive regimens but this drugs needs to be further
investigated (7).
Rejections could also trigger post-transplant aHUS recurrence
(7). The renal allograft endothelium is the primary target of anti-
HLA antibodies. Although antibodies activate the complement
cascade primarily through the classical pathway, one can reason-
ably hypothesize that uncontrolled activation of the alternative
pathway in aHUS patients could further amplify the endothelial
damages induced by anti-HLA antibodies.
CLINICAL PRESENTATION
Patients with post-transplant aHUS usually present with a
microangiopathic hemolytic anemia, thrombocytopenia, and
acute kidney injury. Typical laboratory abnormalities include
an increased serum creatinine; evidence of hemolysis (such as
increased reticulocyte percentage, reticulocytosis, schistocytes on
peripheral smear,and increased serum lactate dehydrogenase); and
a low-platelet count. The urinalysis typically shows hematuria and
only a small amount of proteinuria. Patients with post-transplant
aHUS recurrence may develop fever but the presence of chills and
high-spiking fever should suggest that the presence of infection
that could be the trigger of aHUS recurrence. Recurrence could
also manifest with neurological symptoms such as confusion and
headache. Focal neurological abnormalities (e.g., transient apha-
sia, transient ischemic attack, and stroke) are less frequent, but
grand mal seizures and coma can occur. Imaging studies may show
a pattern consistent with reversible posterior leukoencephalopa-
thy syndrome (PRES) (85). Gastrointestinal symptoms of aHUS
include abdominal pain, nausea, vomiting, and diarrhea. Cardiac
involvement includes diffuse platelet thrombi and associated hem-
orrhage and patches of necrosis in cardiac tissues (e.g., coronary
arteries, myocardium, and conducting system), which may lead
to complications such as arrhythmia, sudden cardiac death, and
myocardial infarction (86).
Some patients may present with only an increased serum cre-
atinine and abnormal urinalysis due to the renal lesion associated
with TMA, and without thrombocytopenia, hemolytic anemia,
or other manifestations (45, 87). In 2014, Stevenson et al. (88)
described a case of unsensitized aHUS patient who received
deceased donor kidney transplant. The patient developed severe
antibody mediated rejection (AMR) that was unresponsive to
aggressive therapy with evidence of new DSA formation. The rejec-
tion led to graft failure. This case suggested that dysregulation
of the alternative complement pathway within the transplanted
kidney may have contributed to the severe AMR. Licht et al.
(89) reported an AMR case, presenting with a systemic throm-
botic microangiopathic process, in a kidney transplant recipient
harboring a homozygous deletion of CFHR3-1. In this patient,
eculizumab rescue therapy rapidly resulted in a complete recov-
ery from the AMR-induced TMA, further supporting the benefit
of complement blockade in severe AMR. There is an ongo-
ing trial that is currently underway to study the efficacy and
safety of Eculizumab for treatment of AMR following kidney
transplantation (www.ClinicalTrials.gov NCT01895127).
The differential diagnosis of post-transplant aHUS recurrence
after kidney transplantation is similar to that of non-kidney trans-
plant patients. This includes TTP and secondary forms of HUS
due to other causes. Shiga toxin-producing E. coli (STEC) induced
HUS is differentiated from aHUS based on demonstrating a recent
exposure to STEC. Thus, screening for STEC should be performed
in these cases. S. pneumoniae induced HUS occurs in a patient
with evidence of a pneumococcal infection (e.g., pneumonia, sep-
sis, or meningitis), which is confirmed by a positive culture of
blood and/or other pertinent tissues. HIV infection should also
be excluded. Other rare non-infectious secondary causes of HUS
include drug toxicity (examples: quinine, anti-platelet therapy,
and chemotherapy), and autoimmune diseases like SLE or anti-
phospholipid syndrome. HELLP syndrome and post-partum HUS
should be kept on the differential diagnosis if the history is sug-
gestive; although recent data showed that complement mutations
were described in 36% of women with HELLP syndrome and
86% of cases of post-partum HUS. Thus, we may conclude that
pregnancy could act as a trigger for aHUS rather than a direct
cause of it.
PREVENTION
For many decades, kidney transplantation was contraindicated
for patients with ESRD secondary to aHUS due to the high-
recurrence rate. However, over the last decade, perceptions on
kidney transplantation in aHUS have changed. Transplantation
may now be considered on a case-by-case basis,with individualized
strategies based on donor characteristics and recipient genetics
findings (5, 7, 90). Certain strategies that primarily target prevent-
ing endothelial damage, that could potentially trigger aHUS in
renal allograft, can be used to make the kidney transplantation suc-
cessful. As mentioned earlier, the kidney transplantation process
leads to transient or continuous endothelial damage in different
mechanisms. This damage may serve as the trigger to alterna-
tive complement pathway activation and subsequently recurrence
in aHUS. These insults are discussed earlier, and include brain
death, ischemia/reperfusion injury, infections, immunosuppres-
sive drugs, and rejection. In theory, strategies that minimize or
halt these insults may lead to better renal allograft outcome.
As mentioned earlier, brain death and ischemia-reperfusion
play a role in complement activation. Thus, aHUS patients,
who are prone to uncontrolled complement activation, may be
more susceptible to delayed graft function and ischemia-induced
irreversible graft damage (5, 51). Therefore, it seems reason-
able to exclude expanded criteria donors with the greatest risk
of delayed graft function, such as non-heart-beating donors or
those with prolonged cold ischemia times, from donation to
aHUS patients. Also, to reduce the burden of post-transplant
endothelial damaging factors, renal transplantation across posi-
tive crossmatches and/or with preformed donor specific antibody
should be evaluated carefully, especially in patients who are highly
sensitized and incompatible donation is the only option avail-
able for transplantation. In our previously published series, few
patients with aHUS received ABO and HLA incompatible kidney
transplantation (62).
Systemic infections have been found to trigger aHUS episodes.
Thus, infections in kidney transplant recipients with aHUS must
be treated aggressively to prevent aHUS recurrence. Particular
attention must be paid to preventing CMV infection with adequate
prophylaxis in kidney transplant recipients with aHUS (5, 71, 91).
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In terms of immunosuppressive drugs, although CNI have been
associated with endothelial toxicity (79, 80) and post-transplant
TMA, a cohort study failed to identify CNI-based regimens as risk
factors for post-transplant aHUS recurrence (51). However, CNI
overexposure may trigger aHUS recurrence, emphasizing the need
of careful CNI blood levels monitoring. On the other hand, mTOR
inhibitors have been independently associated with a greater aHUS
recurrence rate, and should not be used in aHUS patients (5, 51).
Belatacept therapy that has no risk on endothelial injury should be
studied further; it may be considered an alternative maintenance
immunosuppressive therapy in these patients (5, 7).
TYPE OF TRANSPLANT
The type of transplant may play a role in prevention of post-
transplant aHUS recurrence. There are two options for kid-
ney transplantation in patients with aHUS. This includes com-
bined liver–kidney transplantation (CLKT) and isolated kidney
transplantation.
Combined liver–kidney transplantation
The motivation to treat individuals with ESRD due to aHUS by
CLKT is that liver transplant represents the “gene therapy” for
those individuals whose aHUS is due to a defect in a circulating
product synthesized by the liver. However, the early experiences
with CLKT were disappointing. The first five cases did not include
preoperative treatment with plasma therapy and had a fatal out-
come. In three of these cases, there was evidence of complement-
mediated coagulative hepatic necrosis (5, 92–94). As mentioned
earlier, it is suggested that with ischemia/reperfusion, significant
modification in the endothelial happens leads to complement acti-
vation (95, 96). Thus, it was suggested that CLKT should not be
done without a preoperative regimen for complement regulation
such as plasma therapy, or anti-C5 treatment with eculizumab.
Unfortunately, there is no registry that gathers and follows the
outcome of aHUS cases that were treated with liver or combined
liver and kidney transplantation. A summary of more recent cases
that were treated with liver or CLKT was published in 2013 (97).
These cases were also treated with preoperative eculizumab or
plasma therapy. The overall success rate was 16 out of 20 (80%)
and the mortality rate was 3 out of 20 (15%). Out of 20 trans-
plants, 16 were carrier of CFH mutations (14 successful), 1 for
CFB (successful), 1 for C3 (unsuccessful), and 2 for CFH/CFHR1
hybrid mutation (1 successful). One successful transplant was an
isolated liver in a patient with remaining kidney function before
the availability of eculizumab. Plasma therapy alone was used in
18 (15 cases successful) and eculizumab with plasma therapy in 2
(1 successful).
Nevertheless, the risks inherent to the surgery and the safer
newly available alternative preventative and therapeutic options
have made CLKT less favorable for treatment of aHUS. Thus,
the option of CLKT should be pursued on a case-by-case basis,
depending on individual’s physical status, local expertise of the
transplant surgeons, ability to afford a long-term eculizumab
therapy, and patient wishes regarding quality-of-life (5, 90).
Isolated kidney transplantation
Over the last several years, advancements in the management of
aHUS have allowed successful isolated kidney transplantations in
patients with ESRD secondary to aHUS. There is no longer ratio-
nale for barring kidney transplantation in aHUS patients from
deceased donors and from living non-related donors, provided
that anti-C5 treatment with eculizumab is available for prevent-
ing or treating aHUS recurrence. Prior to transplantation, many
centers screen patients for genetic abnormalities in complement
regulatory proteins before inclusion on kidney transplant waiting
lists. It is not acceptable to do the distinction between infection-
induced HUS and aHUS based on prodromic diarrhea alone,
because approximately 20–30% of cases of aHUS are preceded
by diarrhea (7, 24). In the case of living donors, most centers
screen donors and exclude them if they are found to carry muta-
tions in the above-mentioned genes. Historically, living-related
kidney transplantation was contraindicated in aHUS patients in
most centers (1) because of the risk of the donor carrying the
same mutation that the recipient has. However, this recommen-
dation had changed with the recent approaches that have been
used for prevention and treatment of aHUS post-transplantation
recurrence.
PLASMA THERAPY/PLASMAPHERESIS
There is limited published data on the efficacy of prophylactic
plasma therapy to prevent post-transplant aHUS recurrence. It
was first demonstrated to be efficient in preventing post-transplant
aHUS recurrence in patients in whom genetic abnormalities pre-
dicted a high risk of recurrence following kidney transplantation
(5, 51, 53, 61, 91). However, in other studies, prophylactic plasma
therapy failed to prevent post-transplant aHUS recurrence in
some cases (51, 98). In a small sample study (51), nine patients
received preemptive plasma exchange therapy in an attempt to pre-
vent post-transplant recurrence of aHUS. In multivariate analysis,
prophylactic plasma therapy decreased graft loss [RR= 0.11 (0.01–
0.84) p= 0.035]. There was also a non-significant decrease in
disease recurrence [RR= 0.34 (0.10–1.13) p= 0.078] in patients
who received preemptive plasma exchange therapy. In addition to
this, some small studies demonstrated that there was an unpre-
dictable risk of recurrence when plasmapheresis sessions were
progressively spaced out (5, 59, 91). Lastly, the issues of prolonged
adequate vascular access (5), plasma allergy (59), and quality-of-
life (99) should also be taken into account when treating with
long-term plasma therapy. In antibody-induced aHUS (e.g. anti-
CFH antibodies), preventative plasmapheresis is the therapy of
choice. In recent papers, attempts to reduce titers of anti-CFH
antibody with preemptive plasmapheresis and/or rituximab have
enabled successful kidney transplantation in two patients with
aHUS-related ESRD (5, 100, 101).
ECULIZUMAB
Eculizumab is a recombinant humanized monoclonal anti-C5
antibody, licensed initially for the treatment of paroxysmal noc-
turnal hemoglobinuria (2, 102), was recently approved for the
treatment of aHUS (2). Eculizumab binds specifically to the
complement protein C5, halting the complement cascade and
inhibiting production of cell-killing protein complexes (103).
In 2011, Weitz et al. (77) reported the first successful kidney
transplantation in a child with CFH deficient aHUS after the
prophylactic administration of eculizumab. In 2012, Zuber et al.
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(98) in France reported nine patients who received prophylactic
eculizumab therapy to prevent post-transplant aHUS recurrence,
eight of whom experienced a successful recurrence-free post-
transplant course, while one lost his graft from an early graft artery
thrombosis. They all harbored a complement genetic abnormality
associated with a risk of aHUS recurrence >80%. Recently, our
institution (62) reported four patients with aHUS who received
prophylactic eculizumab at the time of transplantation. Three of
them received eculizumab for 6 months post-transplant and one
of them received it as life-long therapy. The four patients did not
develop aHUS recurrence. Earlier in this paper, we included two
new cases of aHUS caused by CFH and CFHRs mutations that
underwent successful kidney transplantation with prophylactic
life-long eculizumab.
Overall, these data suggest that long-term eculizumab treat-
ment is highly effective for the prevention of post-transplant aHUS
recurrence. More studies are needed to determine the optimal
dosing and duration of prophylactic therapy (90).
There are no established guidelines for eculizumab dosing in
prevention of aHUS. In our institution, the first dose is admin-
istered within 24 h before the operation. Prophylactic strategy
should be initiated before the surgery in order to hamper ischemia-
reperfusion injury related complement activation. We continue
with weekly infusion starting on day 1 post-transplant for 4 weeks,
then biweekly infusion. The decision when to stop eculizumab
therapy is based on the patient’s mutation type. We currently rec-
ommend life-long therapy for patients with mutations that are




Earlier studies did not show good outcome with plasmapheresis
alone in the treatment of post-transplant aHUS recurrence. In
Noris et al. paper (1), plasma therapy induced remission in 55–
80% of episodes in patients with CFH, C3, or THBD mutations
or auto-antibodies, whereas patients with CFI (factor-I) muta-
tions were poor responders. In Le Quintrec’s (51) paper, curative
plasma therapy, which consisted either of fresh frozen plasma infu-
sions (n= 3) or plasma exchanges (n= 30), was performed in 33
of the 44 patients (75%) with aHUS recurrence. Overall, graft
outcome was poor in patients who received curative plasma ther-
apy for recurrence in univariate analysis [RR= 2.51 (1.34–4.68)
p= 0.004]. After adjustment for recurrence, multivariate analysis
showed that curative plasma therapy did not improve graft survival
[RR= 1.17 (0.49–2.83) p= 0.7].
ECULIZUMAB
There are multiple case reports and series that showed success with
eculizumab in the treatment of plasmapheresis resistant (104–106)
and dependent aHUS forms (99, 104, 106–108). There are also
some cases where eculizumab was also used as a first line therapy
without any prior plasma therapy (106, 109).
In 2011, Al-Akash et al. (72) reported one case in which
eculizumab with plasmapheresis induced long-term remission in
recurrent post-transplant aHUS associated with C3 gene muta-
tion. In 2012, we reported a case of two post-transplant aHUS
recurrences in a patient with unclassified aHUS. The first recur-
rence responded to plasmapheresis and eculizumab. The second
recurrence was treated successfully with eculizumab alone (104).
Zuber et al. (98) also reported thirteen kidney transplant recipi-
ents were given anti-C5 for post-transplant aHUS recurrence. A
complete reversal of aHUS activity was achieved in all of them.
In this case series, it was noted that the delay of anti-C5 initiation
after the onset of the aHUS episode inversely correlated with the
degree of renal function improvement. Three patients in whom
anti-C5 was subsequently stopped experienced a relapse. Recently,
we presented our center’s data (62), in which three patients with
post-transplant aHUS recurrence after kidney transplantation
were treated with eculizumab and plasmapheresis, two of them
responded to the therapy. The patient who did not response had
CFH mutation.
Legendre et al. (107) have recently published the results of two
trials that studied the efficacy of eculizumab in adults and adoles-
cents with aHUS resistant to plasma therapy (trial 1; 17 patients)
or on chronic plasma therapy (trial 2; 20 patients). These two trials
together included 15 kidney transplant recipients. In both trials,
the primary end point (i.e., normalization of platelet count and
TMA-free status, respectively) was achieved by more than 80% of
the patients. Interestingly, similar to Zuber’s paper, it was noted
that there was an inverse correlation between the onset of the aHUS
recurrence and eculizumab initiation with the recovery of renal
function in both transplanted and non-transplanted patients. In
these 2 studies, 5 out of 18 patients who missed eculizumab doses
developed post-transplant aHUS recurrence. In two case reports,
patients received only a single dose for the treatment of recur-
rent post-transplant aHUS (104, 105). Although both patients had
sustained response with a prolonged aHUS-free period, delayed
recurrence occurred in the first patient after 11.5 months (105)
and in the other after 21 months (104). The reintroduction of
eculizumab led to remission of aHUS in the former patient but
failed to prevent graft loss in the later. In another case report,
a delay of 6 days in the ninth infusion of eculizumab led to a
mild relapse of post- transplant aHUS, but the disease responded
rapidly to the re-initiation of treatment (110).
The studies above illustrate the importance of prompt treat-
ment with eculizumab therapy once a recurrence is diagnosed.
They also show that maintenance treatment is more effective
than single dose therapy in preventing recurrence. There is also
a suggestion that more recurrence occurs when administration of
eculizumab is spaced out by more than every 2 weeks. Altogether,
the available data also illustrate the critical need for prospective
well-controlled studies to address the issue of treatment dosing
and duration.
FUTURE THERAPIES
Concentrated CFH, purified from human plasma, may serve as a
future therapeutic option for aHUS patients with CFH mutations,
especially in patients with a quantitative deficiency in functional
CFH (5, 7). However, there are several questions that need to be
addressed regarding its therapeutic efficacy, bioavailability, poten-
tial dosing, and complications relating to competition between the
plasma-derived CFH and the mutated protein. Also, recombinant
THBD can be utilized in the treatment of aHUS (12). The use
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of recombinant human THBD, which also has anticoagulant and
anti-inflammatory properties, was approved in Japan in 2008 for
the treatment of disseminated intravascular coagulation. Of note,
a case of refractory TMA after hematopoietic stem cell transplan-
tation was published in 2009; the TMA was successfully treated
with recombinant THBD (111). Other complement-modulating
agents under development might represent additional therapeutic
avenues (112) and need more investigation.
SUMMARY
Atypical HUS is characterized by hemolytic anemia, thrombocy-
topenia, and renal impairment that frequently progresses to ESRD.
In more than 50% of patients, mutations in complement regula-
tory proteins or antibodies to these proteins are identified. Among
patients who undergo kidney transplantation, aHUS commonly
recurs, especially in patients who carry mutations. Recurrent
aHUS after kidney transplantation is associated with high rate
of allograft failure. The type of the mutation dictates the over-
all prognosis and the risk of post-transplant recurrence, which
ranges from very minimal up to 80%. Although combined liver
and kidney transplantation provides the “gene therapy” for aHUS,
it remains a high-risk operation and with the successful use of
eculizumab in prevention and treatment of post-transplant aHUS
recurrence, this option became less favorable, although it should
not be overlooked. Isolated kidney transplantation remains the
best option for ESRD due to aHUS. Nonetheless, in the milieu of
kidney transplantation, there are several triggers for aHUS recur-
rence and this includes immunosuppressive drugs, brain-death
related injury, ischemia-reperfusion injury, and infections. Strate-
gies that minimize or block these potential triggers could prevent
aHUS recurrence. The available published data strongly suggest
that the use of prophylactic treatment with eculizumab rather than
plasmapheresis alone. With the limited available data, eculizumab
should be continued indefinitely. Among all transplantation recip-
ients who develop recurrence in aHUS after transplantation, treat-
ment with eculizumab rather than plasmapheresis alone should
be promptly initiated. However, therapy with eculizumab car-
ries its own risks and is associated with meningococcal infections
that can be life threatening. Thus, meningococcal vaccination is
required in all patients treated with eculizumab. There are sev-
eral questions regarding the safety, dosing, and duration of pro-
phylaxis and/or treatment with this drug. The best approach to
answer these questions can be achieved by a prospective controlled
trial.
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